Current pharmacological solutions for Behcet's syndrome.

INTRODUCTION
Behçet's syndrome (BS) has a heterogeneous clinical phenotype and clinical manifestations may respond differently to drugs commonly used to treat BS. The type, dose and duration of immunomodulatory, immunosuppressive and biologic agents should be tailored individually.


AREAS COVERED
We reviewed the literature for articles on BS management that were published until June 2022 and summarized the management options in BS for each type of organ involvement. We aimed to cover all currently available pharmacological agents used in BS, as well as surgical and interventional options, focusing on recent evidence.


EXPERT OPINION
Management aims in BS are to preserve function and quality of life, and to avoid damage. Choice of treatment modalities depends on the organs that are actively involved, severity of involvement and prognostic factors. A treat-to-target strategy would help to improve long-term outcomes in BS.